CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
THERABOT develops innovative biohybrid agents, known as iBots, to enhance bacterial cancer therapy for colorectal cancer. By combining synthetic biology and nanotechnology, these agents improve the delivery of therapeutic bacteria to tumors while minimizing side effects.
THERABOT pioneers a groundbreaking approach in the fight against cancer through the development of engineered biohybrid agents, iBots.
These iBots represent a significant leap in bacterial cancer therapy (BCT), combining synthetic biology and nanotechnology to encapsulate therapeutic bacteria with protective polymeric coatings.
This encapsulation aims to enhance the delivery and efficacy of bacteria to colonize tumor tissue, drastically reducing the adverse immune responses and systemic toxicity…
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, San Sebastian
Type: Research institute
Activity type: Research Organisations
SME: No
Sweden, Uppsala
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
France, AIX EN PROVENCE
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Spain, DONOSTIA/SAN SEBASTIAN
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
